Federated Hermes Inc. Has $1.45 Million Stock Holdings in Glaukos Corporation $GKOS

Federated Hermes Inc. trimmed its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 25.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,730 shares of the medical instruments supplier’s stock after selling 6,093 shares during the quarter. Federated Hermes Inc.’s holdings in Glaukos were worth $1,446,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of GKOS. AlphaQuest LLC increased its position in shares of Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 633 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares during the period. Parkside Financial Bank & Trust increased its holdings in Glaukos by 909.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock worth $129,000 after purchasing an additional 1,128 shares in the last quarter. M&T Bank Corp bought a new position in Glaukos during the 2nd quarter worth about $203,000. Finally, Inspire Advisors LLC acquired a new stake in shares of Glaukos in the 2nd quarter valued at about $208,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

Shares of NYSE GKOS opened at $113.37 on Friday. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average price is $114.22 and its two-hundred day moving average price is $97.34. The company has a market cap of $6.51 billion, a PE ratio of -73.61 and a beta of 0.70. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $161.78.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 10,498 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the completion of the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at $11,793,290.88. This trade represents a 10.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 329,655 shares of company stock worth $37,752,234 in the last quarter. Company insiders own 5.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on GKOS shares. Stephens upped their price objective on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $125.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. UBS Group raised their price target on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. BTIG Research boosted their price objective on shares of Glaukos from $123.00 to $131.00 and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $132.54.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.